Anti-CD122 antibody restores specific CD8+ T cell response in nonalcoholic steatohepatitis and prevents hepatocellular carcinoma growth

Anti-CD122 antibody restores specific CD8+ T cell response in nonalcoholic steatohepatitis and prevents hepatocellular carcinoma growth

Nonalcoholic steatohepatitis (NASH) can lead to hepatocellular carcinoma (HCC). Although immunotherapy is used as first-line treatment for advanced HCC, the impact of NASH on anticancer immunity is only partially characterized. We assessed the tumor-specific T cell immune response in the context of...

Full description

Bibliographic Details
Main Authors: Stéphanie Lacotte, Florence Slits, Beat Moeckli, Andrea Peloso, Stéphane Koenig, Matthieu Tihy, Sofia El Hajji, Quentin Gex, Laura Rubbia-Brandt, Christian Toso
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:OncoImmunology
Subjects:
Hepatocellular carcinoma
immunotherapy
nonalcoholic steatohepatitis
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2184991

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2023.2184991

Similar Items